Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 590 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Motor Neuron Disease Clear all
Recruiting No phase listed Observational

Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)

NCT05354622
View directory record Official record
Conditions
Hereditary Spastic Paraplegia, Neurodegenerative Diseases, Pediatric Disorder, Spasticity, Muscle, Motor Neuron Disease, Movement Disorders
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Month to 30 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 7, 2026, 2:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Cell Death in Spinal Muscular Atrophy

NCT01754441
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2020
U.S. locations
2
States / cities
Wilmington, Delaware • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Jun 7, 2026, 2:15 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Closed Loop Spinal Cord Stimulation for Neuromodulation of Upper Motor Neuron Lesion Spasticity

NCT06384170
View directory record Official record
Conditions
Chronic Pain, Spasticity as Sequela of Stroke, Upper Motor Neuron Lesion
Interventions
Spinal Cord Stimulation- Closed loop
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 7, 2026, 2:15 PM EDT
Completed No phase listed Observational

The E-health Application To Modify ORal Energy Intake and Measure Outcomes REmotely in ALS Clinical Trial (EAT MORE2)

NCT04051333
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALS Nutrition App (MyDataHelps platform)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Jun 7, 2026, 2:15 PM EDT
Completed Early Phase 1 Interventional

SSRIs vs. TCAs for Depression in ALS Patients

NCT02851914
View directory record Official record
Conditions
Depression, Amyotrophic Lateral Sclerosis
Interventions
Tricyclic Antidepressants ("TCA"), Selective Serotonin Uptake Inhibitors ("SSRI")
Drug
Lead sponsor
St. Louis University
Other
Eligibility
25 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Jun 7, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)

NCT01494701
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 14 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jun 7, 2026, 2:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders

NCT05116943
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2030
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 7, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

NCT05053035
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AL001, Placebo
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Tampa, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jun 7, 2026, 2:15 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy

NCT02193074
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
nusinersen, Sham procedure
Drug · Procedure
Lead sponsor
Biogen
Industry
Eligibility
Up to 210 Days
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Jun 7, 2026, 2:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

NCT01083667
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Pyrimethamine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Jun 7, 2026, 2:15 PM EDT
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034
View directory record Official record
Conditions
Adjustment Disorder
Interventions
RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 7, 2026, 2:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Environmental Exposure and Neurological Diseases Questionnaire

NCT02916966
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Patient Registry
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Jun 7, 2026, 2:15 PM EDT
Terminated Phase 2 Interventional

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

NCT03196375
View directory record Official record
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jun 7, 2026, 2:15 PM EDT
Completed No phase listed Observational Results available

DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS

NCT02675075
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Jun 7, 2026, 2:15 PM EDT
Completed Not applicable Interventional

A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS

NCT03324399
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
probiotic
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jun 7, 2026, 2:15 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb

NCT06300996
View directory record Official record
Conditions
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy 4, SMA
Interventions
Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)
Device
Lead sponsor
Marco Capogrosso
Other
Eligibility
16 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jun 7, 2026, 2:15 PM EDT
Not listed Phase 3 Interventional

Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis

NCT00069186
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Creatine Monohydrate
Drug
Lead sponsor
The Avicena Group
Industry
Eligibility
21 Years to 80 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
8
States / cities
San Francisco, California • Kansas City, Kansas • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 7, 2026, 2:15 PM EDT
Completed Not applicable Interventional

Transcutaneous Electrical Stimulation for Spasticity in Patients With Primary Lateral Sclerosis

NCT06012110
View directory record Official record
Conditions
Primary Lateral Sclerosis
Interventions
Transcutaneous electrical stimulation
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Jun 7, 2026, 2:15 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-up Study for Patients From AVXS-101-CL-101

NCT03421977
View directory record Official record
Conditions
Spinal Muscular Atrophy 1
Interventions
Onasemnogene Abeparvovec-xioi
Biological
Lead sponsor
Novartis Gene Therapies
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Jun 7, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT00790582
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
lithium carbonate
Drug
Lead sponsor
Forbes Norris MDA/ALS Research Center
Other
Eligibility
21 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jun 7, 2026, 2:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I

NCT00661453
View directory record Official record
Conditions
Spinal Muscular Atrophy Type I
Interventions
Valproic Acid and Levocarnitine
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Weeks to 12 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
6
States / cities
Baltimore, Maryland • Detroit, Michigan • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Jun 7, 2026, 2:15 PM EDT
Withdrawn Phase 2 Interventional

Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis

NCT03457753
View directory record Official record
Conditions
ALS
Interventions
Riluzole Oral Soluble Film
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2019 · Synced Jun 7, 2026, 2:15 PM EDT
Suspended Phase 1 Interventional

Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis

NCT01082653
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
autologous bone marrow-derived stem cells
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jun 7, 2026, 2:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03160898
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Reldesemtiv, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 80 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
47
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Jun 7, 2026, 2:15 PM EDT